Q-omics provides the consensus-scored PRPF40A profile across patient tissues and cancer cell-line models. PRPF40A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PRPF40A is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, PRPF40A protein abundance shows 30,883 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where PRPF40A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRPF40A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRPF40A survival associations across molecular data types. PRPF40A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRPF40A RNA expression–survival associations across cancer types. High PRPF40A expression shows unfavorable associations in ACC, KIRP, MESO, LIHC and PAAD, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PRPF40A RNA expression.
This table summarizes PRPF40A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PRPF40A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRPF40A shows higher tumor expression in HNSC, BLCA, STAD, LIHC, LUSC and COAD. The HNSC box plot shows higher PRPF40A RNA expression in tumor versus normal tissue (log2 FC = +0.906, t-test p < 0.001).
This table shows molecular features associated with PRPF40A in patient tissues and cancer cell lines. In patient samples, PRPF40A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRPF40A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
